Skip to main content

Table 6 Comparison of treatment effect on relapses and disability violating the positivity assumption

From: Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

  

Intention to treat

Per-protocol

Counts of relapses

IRRc [95%CI]

  

  ATTa

Matching- caliper = 0.1

1.49 [1.36; 1.65]

0.95 [0.86; 1.04]

  ATEb

Weighting by sIPTWd

0.92 [0.85; 0.99]

0.78 [0.70; 0.86]

Time to first relapse

HRe [95%CI]

  

  ATTa

Matching- caliper = 0.1

0.93 [0.79, 1.09]

0.82 [0.72, 0.92]

  ATEb

Weighting by sIPTWd

0.91 [0.83; 1.00]

0.92 [0.79; 1.08]

Time first EDSS worsening

HRe [95%CI]

  

  ATTa

Matching- caliper = 0.1

0.92 [0.78, 1.08]

0.93 [0.75, 1.14]

  ATEb

Weighting by sIPTWd

0.88 [0.65; 1.20]

1.02 [0.77; 1.36]

Time to first EDSS improvement

HRe [95%CI]

  

  ATTa

Matching- caliper = 0.1

1.07 [0.91, 1.26]

1.23 [1.03, 1.47]

  ATEb

Weighting by sIPTWd

0.89 [0.66; 1.19]

1.01 [0.76; 1.35]

  1. aAverage treatment effect for treated
  2. bAverage treatment effect for the entire population
  3. cIncidence Rate Ratio
  4. dStabilized inverse probability of treatment weighting
  5. eHazard ratio